July 2026
Ayahuasca
What July 2026's 5 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research published in July 2026 on ayahuasca was largely preclinical and methodological, with no new clinical efficacy trials reported. A single rat study found that ayahuasca reduced relapse-like alcohol intake and anxiety- and depressive-like behaviors, but effects were sex- and region-dependent, and a scoping review showed that registered human trials remain early-stage and focused on safety rather than disorder-specific outcomes. A theoretical paper cautioned against enthusiasm, emphasizing the need for rigorous methodology before concluding efficacy. Overall, evidence for ayahuasca's therapeutic effects in humans remains preliminary and limited.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Beyond Enthusiasm: Ayahuasca and the Future of Depression Research. 2026 | theoretical | Unclear | Argues that ayahuasca research for depression requires more rigorous methodology and caution before drawing conclusions about efficacy. | |
| Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review 2026 | review | Supports | Reviews evidence that psilocybin from Psilocybe cubensis can sustainably alleviate depressive symptoms with fewer side effects than conventional treatments, though this is about psilocybin, not ayahuasca. | |
| DMT und Ayahuasca / DMT and Ayahuasca 2026 | scientific overview | Unclear | Provides a transdisciplinary overview of DMT and ayahuasca, highlighting unique features such as oral inactivity without MAO inhibitors, ultra-short duration, endogenous occurrence, and the Gonzales v. O Centro ruling. | |
| Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats 2026 | preclinical study | Supports | A single ayahuasca administration reduced relapse-like ethanol intake and attenuated anxiety- and depressive-like behaviors, partially reversing alcohol-induced neurochemical and oxidative changes in a sex- and region-dependent manner. | |
| Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review. 2026 | systematic review | 26 | Mixed | The registry landscape expanded after 2020-2021 but is dominated by early-stage trials focused on acute safety and subjective effects, with limited disorder-specific programs beyond depression. |
Argues that ayahuasca research for depression requires more rigorous methodology and caution before drawing conclusions about efficacy.
theoretical
Reviews evidence that psilocybin from Psilocybe cubensis can sustainably alleviate depressive symptoms with fewer side effects than conventional treatments, though this is about psilocybin, not ayahuasca.
review
Provides a transdisciplinary overview of DMT and ayahuasca, highlighting unique features such as oral inactivity without MAO inhibitors, ultra-short duration, endogenous occurrence, and the Gonzales v. O Centro ruling.
scientific overview
A single ayahuasca administration reduced relapse-like ethanol intake and attenuated anxiety- and depressive-like behaviors, partially reversing alcohol-induced neurochemical and oxidative changes in a sex- and region-dependent manner.
preclinical study
The registry landscape expanded after 2020-2021 but is dominated by early-stage trials focused on acute safety and subjective effects, with limited disorder-specific programs beyond depression.
systematic review Sample size: 26
Points of agreement
- Ayahuasca and its components show potential therapeutic effects in preclinical models, particularly for depression and addiction.
- Current clinical research on ayahuasca is at an early stage, prioritizing safety and subjective effects over disorder-specific efficacy outcomes.
- There is a call for more rigorous methodology and cautious interpretation of ayahuasca's therapeutic potential.
Conflicts
- The theoretical paper cautions against enthusiasm for ayahuasca's efficacy, while the preclinical study reports positive effects on alcohol relapse and depressive-like behaviors.
- The psilocybin review reports sustainable symptom relief, but this is for psilocybin, not ayahuasca, and may not generalize.
Gaps
- No new human clinical efficacy trials for ayahuasca were reported in July 2026.
- Durability of effects beyond short-term follow-up is not established.
- Sex- and region-dependent effects in the rat study suggest need for further investigation.
- Most registered trials exclude psychiatric and medical comorbidities, limiting generalizability.
- Long-term safety and optimal dosing remain understudied.